Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 7/20 | 0.33 |
| ▸ | THRB | P10828 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691529 | 0.90 | LMNA (0.34) | LMNASMN1; SMN2THRBMEN1TSHR | |
| SCHEMBL6690378 | 0.82 | THRB (0.36) | RORCTHRBTSHRLPAR1ALDH1A1 | |
| SCHEMBL6698228 | 0.81 | BCL6 (0.38) | RORCTHRBMEN1KMT2ALPAR1 | |
| SCHEMBL6689993 | 0.81 | RORC (0.48) | RORCTHRB | |
| SCHEMBL6694624 | 0.80 | THRA (0.35) | THRB | |
| SCHEMBL6694613 | 0.76 | RORC (0.31) | LMNASMN1; SMN2RORCTHRBMEN1 | |
| SCHEMBL6692440 | 0.71 | THRB (0.36) | LMNASMN1; SMN2RORCTHRBMEN1 | |
| SCHEMBL6693919 | 0.70 | RORC (0.45) | RORCTHRB | |
| SCHEMBL7348321 | 0.68 | ALDH1A1 (0.40) | SMN1; SMN2RORCTHRBKMT2ALPAR1 | |
| SCHEMBL6695983 | 0.68 | CA12 (0.39) | LMNASMN1; SMN2THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003094845-A2 | PYRIDINE-BASED THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | LMNA 4794/4885SMN1; SMN2 3943/4885RORC 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.